Table 2.

Treatment allocation and clinical outcome

Treatment cohortStudy CDX1307-01 local delivery (n = 57)aClinical outcome for stable disease (mo)Study CDX1307-02 intravenous delivery (n = 30)aClinical outcome for stable disease (mo)
CDX-1307 as single agent0.3 mg i.d. (n = 6)1 (3.5)1 mg i.v. (n = 4)
1.0 mg i.d. (n = 6)3 mg i.v. (n = 4)1 (2.3+)
2.5 mg i.d. (n = 6)10 mg i.v. (n = 3)1 (5.7)
30 mg i.v. (n = 5)1 (6.4)
CDX-1307 + GM-CSF2.5 mg i.d. (n = 7)10 mg i.v. (n = 5)1 (5.3)
30 mg i.v. (n = 3)2 (5.2, 5.2)
CDX-1307 + GM-CSF + poly-ICLC2.5 mg i.d. (n = 6)30 mg i.v. (n = 6)b
CDX-1307 + GM-CSF + resiquimod2.5 mg i.d. (n = 7)b1 (18.2)
CDX-1307 + GM-CSF + poly-ICLC + resiquimod2.5 mg i.c. (n = 10)1 (8.8)
15.0 mg i.c. (n = 9)

Abbreviations: i.d., intradermal injection; i.c., intracutaneous (a combination of intradermal and subcutaneous) injection; i.v., infusion.

  • aData represent CDX-1307 dose levels and administration routes evaluated in each treatment cohort (n).

  • bTwo additional patients, one in each of these cohorts, were enrolled and received GM-CSF but did not receive CDX-1307. These patients are therefore excluded from this table.